Friday, 17 Jan 2020

Biologic/Novel Rx

Datesort ascending Type Title Save
18 Feb 2019 ACR Video QD Clinic - The NP Says the Patient is Flaring
16 Feb 2019 Social The RheumNow Weekly Podcast is up! Info on SEAM-PsA, SEAM trial, MRI T2T, biologics & infection, contraceptive use, ANA negative lupus. View here>> or listen on iTunes or SoundClound
16 Feb 2019 Social Dr Mark Genovese on Filgotinib (jak 1 inhibitor in development) showing no diff in responses despite falling 1, 2, 3 biologics #RWCS2019
14 Feb 2019 News Stopping Biologics Before Joint Surgery: Is Earlier Better?
06 Feb 2019 News Biologic High Out of Pocket Costs for Medicare Patients
31 Jan 2019 Social The rheumatoid arthritis drug Xeljanz saw revenues jump 33% for the year, with total revenues coming in at $1.8 billion in 2018
25 Jan 2019 News RheumNow Podcast – TNFs and the Inflammasome (1.25.19)
21 Jan 2019 News Smoking Doesn't Influence Rituximab Responses in Rheumatoid Arthritis
16 Jan 2019 News Anakinra for Acute Crystal-Induced Arthritis
15 Jan 2019 News IL-6 Blocker Succeeds in Real-World Vasculitis
11 Jan 2019 Social “The road to hell is paved with biologic plausibility”. - Dr. Steve Nissan
07 Jan 2019 News BMS Buyout of Celgene for $74 Billion
02 Jan 2019 News Severe Cutaneous Sarcoid Treated with Tofacitinib
25 Dec 2018 Social TB Testing - Do PPD or IGRA before TNFi or biologic - If negative, start therapy - If Positive, Eval for active TB (Sxs, CXR, C/S); if neg --> LTBI Rx BEFORE biologic - If "Indeterminate", repeat or change test. If same or neg--> start biologic - Do not do annual TST or IGRA
24 Dec 2018 News Best of 2018: Unproven But Profitable Stem Cell Clinics
30 Nov 2018 Social AstraZeneca today announced the FDA has granted Orphan Drug Status for Fasenra (benralizumab) for Eosinophilic Granulomatosis with Polyangiitis (EGPA). Fasenra is also approved for severe, eosinophilic asthma
29 Nov 2018 News Kallikrein Inhibitor Lanadelumab Prevents Hereditary Angioedema Attacks
29 Nov 2018 Social UK's NHS has spent £400million on Humira for 46,000 UK patients and starting in December will replace it with biosimilars of adalimumab at a cost of £100million
28 Nov 2018 News FDA Approves Biosimilar Rituximab for NHL, not RA
25 Nov 2018 Social Clinical Trials Benchmark for Biosimilar Development is one of several educational videos available in the "Therapeutic Update: Biosimilars in Rheumatology" video series, sponsored by Sandoz, Inc. and now available on RheumNow.